{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:06:28Z","timestamp":1790262388111,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1-3","license":[{"start":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T00:00:00Z","timestamp":1400284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s12026-014-8537-9","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T11:30:11Z","timestamp":1400239811000},"page":"220-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Applying biodegradable particles to enhance cancer vaccine efficacy"],"prefix":"10.1007","volume":"59","author":[{"given":"Kawther K.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Geary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliasger K.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,17]]},"reference":[{"key":"8537_CR1","unstructured":"Hoyert DL Xu J. Deaths: preliminary data for 2011. Hyattsville: National Center for Health Statistics 2012 2\/22\/2014. Report No.: 6."},{"key":"8537_CR2","doi-asserted-by":"crossref","unstructured":"Edwards BK, Noone A-M, Mariotto AB, Simard EP, Boscoe FP, Henley SJ et al. Annual report to the nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2013:n\/a-n\/a. doi: 10.1002\/cncr.28509 .","DOI":"10.1002\/cncr.28509"},{"issue":"3","key":"8537_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","volume":"105","author":"A Jemal","year":"2013","unstructured":"Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual report to the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175\u2013201. doi: 10.1093\/jnci\/djs491 .","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8537_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00873229","volume":"12","author":"NH Patel","year":"1994","unstructured":"Patel NH, Rothenberg ML. Multidrug resistance in cancer chemotherapy. Invest New Drugs. 1994;12(1):1\u201313.","journal-title":"Invest New Drugs"},{"issue":"25","key":"8537_CR5","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","volume":"27","author":"DG McNeel","year":"2009","unstructured":"McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27(25):4047\u201354. doi: 10.1200\/JCO.2008.19.9968 .","journal-title":"J Clin Oncol"},{"issue":"23","key":"8537_CR6","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","volume":"15","author":"DM Lubaroff","year":"2009","unstructured":"Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, et al. Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res. 2009;15(23):7375\u201380. doi: 10.1158\/1078-0432.ccr-09-1910 .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8537_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrurol.2013.8","volume":"10","author":"SM Geary","year":"2013","unstructured":"Geary SM, Lemke CD, Lubaroff DM, Salem AK. Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol. 2013;10(3):149\u201360. doi: 10.1038\/nrurol.2013.8 .","journal-title":"Nat Rev Urol"},{"key":"8537_CR8","first-page":"154","volume":"26","author":"EF McCarthy","year":"2006","unstructured":"McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154\u20138.","journal-title":"Iowa Orthop J"},{"key":"8537_CR9","first-page":"205","volume":"6","author":"HC Nauts","year":"1946","unstructured":"Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 1946;6:205\u201316.","journal-title":"Cancer Res"},{"issue":"25","key":"8537_CR10","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"OJ Finn","year":"2008","unstructured":"Finn OJ. Cancer Immunology. N Engl J Med. 2008;358(25):2704\u201315. doi: 10.1056\/NEJMra072739 .","journal-title":"N Engl J Med"},{"issue":"6","key":"8537_CR11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/12.6.807","volume":"12","author":"G Becker De","year":"2000","unstructured":"De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol. 2000;12(6):807\u201315.","journal-title":"Int Immunol"},{"issue":"3","key":"8537_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","volume":"22","author":"TW Dubensky Jr","year":"2010","unstructured":"Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010;22(3):155\u201361. doi: 10.1016\/j.smim.2010.04.007 .","journal-title":"Semin Immunol"},{"issue":"5","key":"8537_CR13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","volume":"20","author":"MA Neller","year":"2008","unstructured":"Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol. 2008;20(5):286\u201395. doi: 10.1016\/j.smim.2008.09.006 .","journal-title":"Semin Immunol"},{"issue":"1","key":"8537_CR14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2051-1426-1-12","volume":"1","author":"T Harris","year":"2013","unstructured":"Harris T, Drake C. Primer on tumor immunology and cancer immunotherapy. J ImmunoTherapy Cancer. 2013;1(1):12.","journal-title":"J ImmunoTherapy Cancer"},{"issue":"11","key":"8537_CR15","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1073\/pnas.90.11.4942","volume":"90","author":"M Kovacsovics-Bankowski","year":"1993","unstructured":"Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA. 1993;90(11):4942\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8537_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.0105-2896.2005.00301.x","volume":"207","author":"KL Rock","year":"2005","unstructured":"Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev. 2005;207:166\u201383. doi: 10.1111\/j.0105-2896.2005.00301.x .","journal-title":"Immunol Rev"},{"issue":"12","key":"8537_CR17","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.4161\/hv.26136","volume":"9","author":"VB Joshi","year":"2013","unstructured":"Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum Vaccin Immunother. 2013;9(12):2584\u201390. doi: 10.4161\/hv.26136 .","journal-title":"Hum Vaccin Immunother."},{"key":"8537_CR18","author":"VB Joshi","year":"2013","unstructured":"Joshi VB, Geary SM, Gross BP, Wongrakpanich A, Norian LA, Salem AK. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines. 2013;. doi: 10.1586\/14760584.2014.851606 .","journal-title":"Expert Rev Vaccines."},{"issue":"3","key":"8537_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.addr.2004.09.008","volume":"57","author":"T Storni","year":"2005","unstructured":"Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57(3):333\u201355. doi: 10.1016\/j.addr.2004.09.008 .","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"8537_CR20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2217\/fon.09.6","volume":"5","author":"P Kalinski","year":"2009","unstructured":"Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol. 2009;5(3):379\u201390. doi: 10.2217\/fon.09.6 .","journal-title":"Future Oncol."},{"issue":"8","key":"8537_CR21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3(8):630\u201341.","journal-title":"Nat Rev Immunol"},{"key":"8537_CR22","doi-asserted-by":"crossref","unstructured":"Foon KA, Safa MM. Activating the immune system to fight cancer. Oncol Issues. 2008:18\u201324.","DOI":"10.1080\/10463356.2008.11884287"},{"issue":"5","key":"8537_CR23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/adma.200701689","volume":"20","author":"Y Krishnamachari","year":"2008","unstructured":"Krishnamachari Y, Pearce ME, Salem AK. Self-assembly of cell\u2013microparticle hybrids. Adv Mater. 2008;20(5):989\u201393. doi: 10.1002\/adma.200701689 .","journal-title":"Adv Mater"},{"issue":"2","key":"8537_CR24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","volume":"28","author":"Y Krishnamachari","year":"2011","unstructured":"Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm Res. 2011;28(2):215\u201336. doi: 10.1007\/s11095-010-0241-4 .","journal-title":"Pharm Res"},{"issue":"6","key":"8537_CR25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4155\/tde.13.37","volume":"4","author":"R Agarwal","year":"2013","unstructured":"Agarwal R, Roy K. Intracellular delivery of polymeric nanocarriers: a matter of size, shape, charge, elasticity and surface composition. Ther Deliv. 2013;4(6):705\u201323. doi: 10.4155\/tde.13.37 .","journal-title":"Ther Deliv."},{"issue":"1","key":"8537_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/14712598.5.1.23","volume":"5","author":"ME El-Sayed","year":"2005","unstructured":"El-Sayed ME, Hoffman AS, Stayton PS. Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin Biol Ther. 2005;5(1):23\u201332. doi: 10.1517\/14712598.5.1.23 .","journal-title":"Expert Opin Biol Ther."},{"key":"8537_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.colsurfb.2012.01.021","volume":"94","author":"LH Guerreiro","year":"2012","unstructured":"Guerreiro LH, Da Silva D, Ricci-Junior E, Girard-Dias W, Mascarenhas CM, Sola-Penna M, et al. Polymeric particles for the controlled release of human amylin. Colloids Surf B Biointerf. 2012;94:101\u20136. doi: 10.1016\/j.colsurfb.2012.01.021 .","journal-title":"Colloids Surf B Biointerf"},{"issue":"2\u20133","key":"8537_CR28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0168-3659(99)00078-4","volume":"60","author":"Z Yang","year":"1999","unstructured":"Yang Z, Birkenhauer P, Julmy F, Chickering D, Ranieri JP, Merkle HP, et al. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J Control Release. 1999;60(2\u20133):269\u201377.","journal-title":"J Control Release."},{"issue":"11","key":"8537_CR29","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1021\/cr940351u","volume":"99","author":"KE Uhrich","year":"1999","unstructured":"Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181\u201398.","journal-title":"Chem Rev"},{"issue":"3","key":"8537_CR30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1517\/17425247.2013.751371","volume":"10","author":"OS Kluin","year":"2013","unstructured":"Kluin OS, van der Mei HC, Busscher HJ, Neut D. Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis. Expert Opin Drug Deliv. 2013;10(3):341\u201351. doi: 10.1517\/17425247.2013.751371 .","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"8537_CR31","first-page":"8","volume":"3","author":"SKSAK Prusty","year":"2010","unstructured":"Prusty SKSAK. Toxicological and regulatory consideration of pharmaceutically important nanoparticles. J Curr Pharm Res. 2010;3(1):8\u201312.","journal-title":"J Curr Pharm Res."},{"key":"8537_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/978-1-4939-0345-0_35","volume":"1139","author":"VB Joshi","year":"2014","unstructured":"Joshi VB, Geary SM, Salem AK. Production of antigen-loaded biodegradable nanoparticles and uptake by dendritic cells. Methods Mol Biol. 2014;1139:453\u201366. doi: 10.1007\/978-1-4939-0345-0_35 .","journal-title":"Methods Mol Biol"},{"issue":"5","key":"8537_CR33","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1021\/mp100464y","volume":"8","author":"CD Lemke","year":"2011","unstructured":"Lemke CD, Graham JB, Geary SM, Zamba G, Lubaroff DM, Salem AK. Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. Mol Pharm. 2011;8(5):1652\u201361. doi: 10.1021\/mp100464y .","journal-title":"Mol Pharm"},{"issue":"2","key":"8537_CR34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11095-010-0241-4","volume":"28","author":"Y Krishnamachari","year":"2011","unstructured":"Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm Res. 2011;28(2):215\u201336. doi: 10.1007\/s11095-010-0241-4 .","journal-title":"Pharm Res"},{"issue":"2","key":"8537_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322. doi: 10.1016\/j.jconrel.2012.01.043 .","journal-title":"J Control Release."},{"issue":"5","key":"8537_CR36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s11095-008-9800-3","volume":"26","author":"C Vauthier","year":"2009","unstructured":"Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26(5):1025\u201358. doi: 10.1007\/s11095-008-9800-3 .","journal-title":"Pharm Res"},{"issue":"7","key":"8537_CR37","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1016\/j.actbio.2011.03.023","volume":"7","author":"MP Torres","year":"2011","unstructured":"Torres MP, Wilson-Welder JH, Lopac SK, Phanse Y, Carrillo-Conde B, Ramer-Tait AE, et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater. 2011;7(7):2857\u201364. doi: 10.1016\/j.actbio.2011.03.023 .","journal-title":"Acta Biomater"},{"issue":"4","key":"8537_CR38","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jbm.a.30545","volume":"76","author":"MJ Kipper","year":"2006","unstructured":"Kipper MJ, Wilson JH, Wannemuehler MJ, Narasimhan B. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J Biomed Mater Res, Part A. 2006;76(4):798\u2013810. doi: 10.1002\/jbm.a.30545 .","journal-title":"J Biomed Mater Res, Part A"},{"issue":"3","key":"8537_CR39","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1016\/j.actbio.2012.11.001","volume":"9","author":"VB Joshi","year":"2013","unstructured":"Joshi VB, Geary SM, Carrillo-Conde BR, Narasimhan B, Salem AK. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles. Acta Biomater. 2013;9(3):5583\u20139. doi: 10.1016\/j.actbio.2012.11.001 .","journal-title":"Acta Biomater"},{"issue":"10","key":"8537_CR40","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.biomaterials.2012.12.030","volume":"34","author":"CD Lemke","year":"2013","unstructured":"Lemke CD, Geary SM, Joshi VB, Salem AK. Antigen-coated poly alpha-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations. Biomaterials. 2013;34(10):2524\u20139. doi: 10.1016\/j.biomaterials.2012.12.030 .","journal-title":"Biomaterials"},{"issue":"1\u20132","key":"8537_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0264-410X(02)00435-8","volume":"21","author":"I Gutierro","year":"2002","unstructured":"Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine. 2002;21(1\u20132):67\u201377.","journal-title":"Vaccine."},{"issue":"1","key":"8537_CR42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4161\/hv.4.1.4886","volume":"4","author":"J Wendorf","year":"2008","unstructured":"Wendorf J, Chesko J, Kazzaz J, Ugozzoli M, Vajdy M, O\u2019Hagan D, et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Human Vaccines. 2008;4(1):44\u20139.","journal-title":"Human Vaccines."},{"issue":"2","key":"8537_CR43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2010.02.013","volume":"144","author":"LJ Cruz","year":"2010","unstructured":"Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release. 2010;144(2):118\u201326. doi: 10.1016\/j.jconrel.2010.02.013 .","journal-title":"J Control Release."},{"issue":"9","key":"8537_CR44","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1586\/erv.10.89","volume":"9","author":"MO Oyewumi","year":"2010","unstructured":"Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095\u2013107. doi: 10.1586\/erv.10.89 .","journal-title":"Expert Rev Vaccines."},{"issue":"1","key":"8537_CR45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12248-012-9418-6","volume":"15","author":"VB Joshi","year":"2013","unstructured":"Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85\u201394. doi: 10.1208\/s12248-012-9418-6 .","journal-title":"AAPS J."},{"issue":"6","key":"8537_CR46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0966-842X(01)02039-X","volume":"9","author":"AM Krieg","year":"2001","unstructured":"Krieg AM. Now I know my CpGs. Trends Microbiol. 2001;9(6):249\u201352.","journal-title":"Trends Microbiol"},{"issue":"6","key":"8537_CR47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0264-410X(00)00249-8","volume":"19","author":"AM Krieg","year":"2000","unstructured":"Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000;19(6):618\u201322.","journal-title":"Vaccine."},{"key":"8537_CR48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709\u201360. doi: 10.1146\/annurev.immunol.20.100301.064842 .","journal-title":"Annu Rev Immunol"},{"issue":"6522","key":"8537_CR49","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","volume":"374","author":"AM Krieg","year":"1995","unstructured":"Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546\u20139. doi: 10.1038\/374546a0 .","journal-title":"Nature"},{"key":"8537_CR50","unstructured":"Murphy KP. The induced responses of innate immunity. Janeway\u2019s Immunobiology. New York: Garland Science; 2011. p. 75\u2013125."},{"issue":"3","key":"8537_CR51","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1189\/jlb.71.3.538","volume":"71","author":"TH Chuang","year":"2002","unstructured":"Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol. 2002;71(3):538\u201344.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"8537_CR52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.onc.1210911","volume":"27","author":"AM Krieg","year":"2008","unstructured":"Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161\u20137. doi: 10.1038\/sj.onc.1210911 .","journal-title":"Oncogene"},{"issue":"1","key":"8537_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.smim.2003.10.009","volume":"16","author":"F Takeshita","year":"2004","unstructured":"Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol. 2004;16(1):17\u201322.","journal-title":"Semin Immunol"},{"key":"8537_CR54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2172-11-45","volume":"11","author":"P Cerkovnik","year":"2010","unstructured":"Cerkovnik P, Novakovic BJ, Stegel V, Novakovic S. Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. BMC Immunol. 2010;11:45. doi: 10.1186\/1471-2172-11-45 .","journal-title":"BMC Immunol."},{"issue":"10","key":"8537_CR55","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood.V92.10.3730","volume":"92","author":"HM Liu","year":"1998","unstructured":"Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998;92(10):3730\u20136.","journal-title":"Blood"},{"issue":"2","key":"8537_CR56","first-page":"394","volume":"63","author":"AD Sandler","year":"2003","unstructured":"Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003;63(2):394\u20139.","journal-title":"Cancer Res"},{"key":"8537_CR57","doi-asserted-by":"crossref","unstructured":"Mueller M, Reichardt W, Koerner J, Groettrup M. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J Control Release. 2012;162(1):159\u201366. doi: 10.1016\/j.jconrel.2012.06.015 .","DOI":"10.1016\/j.jconrel.2012.06.015"},{"issue":"3","key":"8537_CR58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.addr.2008.12.003","volume":"61","author":"AK Salem","year":"2009","unstructured":"Salem AK, Weiner GJ. CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Deliv Rev. 2009;61(3):193\u20134. doi: 10.1016\/j.addr.2008.12.003 .","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"8537_CR59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.addr.2008.12.013","volume":"61","author":"Y Krishnamachari","year":"2009","unstructured":"Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev. 2009;61(3):205\u201317. doi: 10.1016\/j.addr.2008.12.013 .","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"8537_CR60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00262-011-1038-y","volume":"60","author":"SM Geary","year":"2011","unstructured":"Geary SM, Lemke CD, Lubaroff DM, Salem AK. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother. 2011;60(9):1309\u201317. doi: 10.1007\/s00262-011-1038-y .","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"8537_CR61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/pcan.2010.57","volume":"14","author":"CD Lemke","year":"2011","unstructured":"Lemke CD, Graham JB, Lubaroff DM, Salem AK. Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse. Prostate Cancer Prostatic Dis. 2011;14(2):118\u201321. doi: 10.1038\/pcan.2010.57 .","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"8537_CR62","doi-asserted-by":"crossref","first-page":"e24523","DOI":"10.4161\/onci.24523","volume":"2","author":"SM Geary","year":"2013","unstructured":"Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology. 2013;2(5):e24523. doi: 10.4161\/onci.24523 .","journal-title":"Oncoimmunology."},{"issue":"20","key":"8537_CR63","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.94.20.10833","volume":"94","author":"GJ Weiner","year":"1997","unstructured":"Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997;94(20):10833\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"16","key":"8537_CR64","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1073\/pnas.96.16.9305","volume":"96","author":"G Hartmann","year":"1999","unstructured":"Hartmann G, Weiner GJ, Krieg AM. CpG DNA a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999;96(16):9305\u201310.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"49","key":"8537_CR65","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1073\/pnas.1313152110","volume":"110","author":"A Titta de","year":"2013","unstructured":"de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies AJ, et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013;110(49):19902\u20137. doi: 10.1073\/pnas.1313152110 .","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"8537_CR66","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CJI.0b013e31802fd8c6","volume":"30","author":"XQ Zhang","year":"2007","unstructured":"Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother. 2007;30(5):469\u201378. doi: 10.1097\/CJI.0b013e31802fd8c6 .","journal-title":"J Immunother"},{"issue":"7085","key":"8537_CR67","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature04596","volume":"440","author":"JM Blander","year":"2006","unstructured":"Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(7085):808\u201312. doi: 10.1038\/nature04596 .","journal-title":"Nature"},{"issue":"12","key":"8537_CR68","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1002\/jps.20978","volume":"96","author":"XQ Zhang","year":"2007","unstructured":"Zhang XQ, Dahle CE, Weiner GJ, Salem AK. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci. 2007;96(12):3283\u201392. doi: 10.1002\/jps.20978 .","journal-title":"J Pharm Sci"},{"issue":"4","key":"8537_CR69","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00262-008-0574-6","volume":"58","author":"R Goforth","year":"2009","unstructured":"Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother. 2009;58(4):517\u201330. doi: 10.1007\/s00262-008-0574-6 .","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"8537_CR70","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00262-011-0973-y","volume":"60","author":"H Shirota","year":"2011","unstructured":"Shirota H, Klinman DM. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother. 2011;60(5):659\u201369. doi: 10.1007\/s00262-011-0973-y .","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"8537_CR71","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1158\/0008-5472.CAN-07-6023","volume":"68","author":"S Nierkens","year":"2008","unstructured":"Nierkens S, den Brok MH, Sutmuller RP, Grauer OM, Bennink E, Morgan ME, et al. In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res. 2008;68(13):5390\u20136. doi: 10.1158\/0008-5472.can-07-6023 .","journal-title":"Cancer Res"},{"key":"8537_CR72","doi-asserted-by":"crossref","unstructured":"Gross BP, Wongrakpanich A, Francis M, Joshi VB, Salem AK, Norian LA, editors. Therapeutic microparticle-based tumor lysate vaccination reduces spontaneous lung metastases in a murine breast cancer model. AACR Annual Meeting 2014; San Diego, CA, USA.","DOI":"10.1158\/1538-7445.AM2014-2885"},{"key":"8537_CR73","unstructured":"Joshi V, Salem AK, editors. Novel formulation strategies for preparation of doxorubicin and CpG Oligonucleotides Loaded PLGA Particles. 2013 AAPS Annual Meeting and Exposition; 2013; San Antonio, TX, USA."},{"issue":"12","key":"8537_CR74","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691\u2013701. doi: 10.1084\/jem.20050915 .","journal-title":"J Exp Med"},{"issue":"12","key":"8537_CR75","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","volume":"16","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16(12):3100\u20134. doi: 10.1158\/1078-0432.ccr-09-2891 .","journal-title":"Clin Cancer Res"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-014-8537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-014-8537-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-014-8537-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T05:26:46Z","timestamp":1689226006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-014-8537-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,17]]},"references-count":75,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["8537"],"URL":"https:\/\/doi.org\/10.1007\/s12026-014-8537-9","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,17]]}}}